Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Invivyd, Inc. - Common Stock (NQ: IVVD )

0.8425 +0.0025 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People
Invivyd Inc (NASDAQ: IVVD) announced additional initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal  
Via Benzinga
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
What 4 Analyst Ratings Have To Say About Invivyd
Via Benzinga
Invivyd: Q1 Earnings Insights
Via Benzinga
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
From Invivyd
Via GlobeNewswire
Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19
Invivyd Inc (NASDAQ: IVVD) announces initial data from its ongoing Phase 1 healthy volunteer clinical trial of VYD222, its investigational monoclonal  
Via Benzinga
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
Earnings Preview: Invivyd
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Invivyd to Participate at the Jefferies Healthcare Conference
From Invivyd
Via GlobeNewswire
INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:IVVD Long Term Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc.
San Diego, CA -- (SBWIRE) -- 05/25/2023 -- An investigation was announced on behalf of investors in shares of Invivyd, Inc. (NASDAQ:IVVD) over possible breaches of fiduciary duties by certain directors... 
Via SBWire
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of... 
Via Benzinga
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
From Invivyd
Via GlobeNewswire
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
From Invivyd
Via GlobeNewswire
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
IVVD DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
INVIVYD DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Invivyd, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVIVYD 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD)
From The Law Offices of Frank R. Cruz
Via Business Wire
IVVD FINAL DEADLINE MONDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI
From The Rosen Law Firm PA
Via GlobeNewswire
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
A clinical trial generating safety, pharmacokinetics, and dosing data with the goal of providing information to allow for rapid advancement into a pivotal Phase 3 trial 
From Invivyd
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RYVYL, Invivyd, Honda, and Allianz and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.